SBIR Phase II: COVID-19 Rapid Sensing Using Structural DNA Biosensors

SBIR 第二阶段：使用结构 DNA 生物传感器快速检测 COVID-19

• 批准号: 2127436
• 负责人: Xiaohu Yao
• 金额: $ 99.85万
• 依托单位: ATOM BIOWORKS INC
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2127436&HistoricalAwards=false
• 关键词: SBIR; Phase; II; COVID; 19

The broader impact of this Small Business Innovation Research (SBIR) Phase I project will be the development of a platform technology for creating rapid virus diagnostics that directly recognizes the virus surface protein pattern from a patient sample and generates accurate results within minutes. Current standards for high-fidelity viral pathogen diagnostics require complex instruments, technical expertise to run the instruments, and hours to produce and interpret results. The proposed platform creates a virus-specific biosensor that selectively binds to the target virus and produces visible results without time-consuming pre-processing or expensive instruments. Lower cost tests and faster sample-to-result turnovers could result in more effective control of disease spread.This project seeks to develop a highly functional, sensitive, and specific diagnostic for the detection of coronavirus. This technology is based on the company’s Pattern-Recognition Enhanced Sensing and Therapeutics (PEST) concept. The solution is a first-in-class diagnostics that uses algorithmically-designed structural DNA to form a trap that may detect and selectively bind a signature pattern of the pathogen. This recognition and binding may generate visual signals without the need of DNA/RNA preprocessing or amplification associated with the current generation of molecular tests (polymerase chain reactions, PCRs). This project will involve building a preclinical prototype of PEST-enabled lateral flow based COVID-19 rapid diagnostics with a goal of providing results for each sample within 5 minutes. This fast test result will be followed by preclinical validation to determine the test’s specificity, limits of detection, and implement mechanism to improve the assay specificity and to avoid cross-reaction to other virus types.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目的更广泛影响将是开发一种平台技术，用于创建快速病毒诊断，该技术直接从患者样本中直接识别病毒表面蛋白质模式，并在几分钟内产生准确的结果。高保真病毒病原体诊断的当前标准需要复杂的工具，运行工具的技术专长以及产生和解释结果的时间。所提出的平台创建了一种病毒特异性的生物传感器，可有选择地与靶病毒结合，并在没有时间耗时的预处理或昂贵的仪器的情况下产生可见的结果。较低的成本测试和更快的样本到回归流失可能会导致对疾病扩散的更有效控制。该项目旨在为检测冠状病毒而开发高度功能，敏感和特定的诊断。该技术基于公司的模式识别增强的感应和治疗学（PEST）概念。该解决方案是使用算法设计的结构DNA的第一类诊断，以形成一个可以检测并选择性地结合病原体的签名模式的陷阱。这种识别和结合可能会产生视觉信号，而无需与当前产生的分子测试（聚合酶链反应，PCR）相关的DNA/RNA预处理或扩增。该项目该奖项反映了NSF的法定任务，并被认为值得在5分钟内为每个样本提供结果。此快速测试结果将进行临床前验证，以确定测试的特异性，检测限制和实施机制，以提高测定特异性并避免与其他病毒类型的交叉反应。该奖项反映了NSF的法定任务，并通过使用基金会的知识分子优点和更广泛的影响评估标准来评估值得支持。